- Company
- About Us
- Management Team
- Board of Directors
- Collaborations
- Careers
- Contact Us
- Science
- Onco-Metabolism Platform
- Therapeutic Areas
- Publications
- Programs
- Pipeline
- Glutaminase Inhibitor Telaglenastat
- Arginase Inhibitor INCB001158
- Arginase Inhibitor
CB-280 - CD73 Inhibitor
CB-708 - Clinical Trials
- Clinical Trials Overview
- Expanded Access
- Media & Investors
- Corporate Profile
- Press Releases
- Event & Presentations
- Stock Information
- Financial Information
- Overview
- SEC Filings
- Ownership Summary
- Analyst Coverage
- Corporate Governance
- Highlights
- Board of Directors
- Management Team
- Committee Composition
- Shareholder Services
Science
Publications and Presentations
Check out our publications and poster presentations.
April 2019
Reversal of adenosine-mediated immune suppression by CB-708, an orally bioavailable and potent small molecule inhibitor of CD73American Association of Cancer Research
February 2019
Telaglenastat(CB-839), a glutaminaseinhibitor, in combination with cabozantinibin patients with clear cell and papillary metastatic renal cell cancer (mRCC): Results of a Phase 1 studyAmerican Society of Clinical Oncology Genitourinary Cancer Symposium
February 2019
CANTATA: Randomized, global, double-blind study of telaglenastat (CB-839) plus cabozanBnib vs. cabozanBnib plus placebo in paBents with metastaBc renal cell carcinomaAmerican Society of Clinical Oncology Genitourinary Cancer Symposium
December 2018
June 2018
Phase 1 clinical trial of the glutaminase inhibitor CB-839 plus capecitabine in patients with advanced solid tumorsAmerican Society of Clinical Oncology
Our Pipeline
We are focused on solid tumors for
which new treatments are urgently needed.